Table 1.
Baseline Patient Characteristics, Overall and by Hepatitis C Virus Genotypea
| HCV Genotype | |||||
|---|---|---|---|---|---|
| Overall(n = 295)b | GT1(n = 235)c | GT2(n = 14) | GT3(n = 34) | GT4(n = 11) | |
| Median age(IQR), y | 52(48–56) | 52(47–56) | 51(48–59) | 54(51–59) | 52(47–60) |
| Male sex | 227(77) | 184(78) | 10(71) | 25(74) | 7(64) |
| Indigenous ethnicityd | 38(13) | 30(13) | 3(21) | 4(12) | 1(9) |
| Detectable HIV RNA(≥50 copies/mL) | 31(11) | 27(11) | 0 | 1(3) | 2(18) |
| Median CD4 count(IQR), cells/μL | 500(300–700) | 500(330–710) | 360(260–550) | 450(230–620) | 580(330–770) |
| Nadir CD4 count ≤200 cells/μLe | 161(59) | 125(58) | 8(62) | 23(74) | 4(40) |
| HCV interferon treatment experienced | 91(31) | 72(31) | 3(21) | 10(29) | 6(55) |
| Cirrhosis | 85(29) | 65(28) | 4(29) | 13(38) | 3(27) |
| Median HCV viral load(IQR), log10 IU/mL | 6.1(5.6–6.5) | 6.1(5.7–6.4) | 6.5(5.9–6.7) | 5.8(5.1–6.4) | 5.9(5.6–6.5) |
| Any additional comorbid condition | 55(19) | 39(17) | 5(36) | 10(29) | 1(9) |
| Diabetes | 27(9) | 19(8) | 4(29) | 4(12) | 0 |
| Chronic kidney disease | 27(9) | 20(9) | 1(7) | 5(15) | 1(9) |
| Hepatitis B coinfection | 6(2) | 4(2) | 0 | 2(6) | 0 |
| Problematic substance use in last year | 124(42) | 99(42) | 5(36) | 17(50) | 2(18) |
| High frequency injection drug use | 58(20) | 47(20) | 1(7) | 10(29) | 0 |
| Hazardous alcohol consumption | 88(30) | 69(29) | 5(36) | 11(32) | 2(18) |
| Off-label or low-efficacy HCV treatmentf | 111(38) | 65(28) | 14(100) | 25(76) | 7(70) |
Abbreviations: GT, genotype; HCV, hepatitis C virus; IQR, interquartile range; IU, international units.
aAll values are No.(%), unless otherwise indicated.
bOne patient was missing data on HCV genotype.
cFor genotype 1176 patients had genotype 1a, 39 had genotype 1b, and 20 had an unspecified genotype 1.
dOverall ethnicity: Caucasian(n = 233), Indigenous(n = 38), black(n = 14), and Asian(n = 10).
eTwenty-four patients were missing data for nadir CD4 count ≤200 cells/μL: 19 for genotype 1, 1 for genotype 2, 3 for genotype 3, and 1 each for genotype 4 and the missing genotype.
fSix patients were missing data for the off-label indication: 4 for genotype 1 and 1 each for genotypes 3 and 4.